MIST vs. SPRY
MIST (Milestone Pharmaceuticals Inc.) and SPRY (Silverback Therapeutics Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, MIST returned -26.40%/yr vs -20.88%/yr for SPRY. At a 0.20 correlation, their price movements are largely independent.
Performance
MIST vs. SPRY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MIST achieves a -35.64% return, which is significantly lower than SPRY's -11.76% return.
MIST
- 1D
- -0.76%
- 1M
- -7.80%
- YTD
- -35.64%
- 6M
- -33.33%
- 1Y
- -26.14%
- 3Y*
- -25.55%
- 5Y*
- -26.40%
- 10Y*
- —
SPRY
- 1D
- 3.01%
- 1M
- 29.47%
- YTD
- -11.76%
- 6M
- -6.80%
- 1Y
- -37.96%
- 3Y*
- 17.85%
- 5Y*
- -20.88%
- 10Y*
- —
MIST vs. SPRY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
MIST Milestone Pharmaceuticals Inc. | -35.64% | -14.41% | 41.32% | -57.83% | -39.54% | -2.24% | -0.00% |
SPRY Silverback Therapeutics Inc | -11.76% | 10.43% | 92.52% | -35.76% | 28.08% | -85.63% | 59.79% |
Correlation
The correlation between MIST and SPRY is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.28 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Dec 4, 2020 | 0.20 |
Fundamentals
MIST:
$169.37M
SPRY:
$1.02B
MIST:
-$0.49
SPRY:
-$2.00
MIST:
63.20
SPRY:
10.26
MIST:
4.70
SPRY:
16.65
MIST:
$1.78M
SPRY:
$98.99M
MIST:
$1.75M
SPRY:
$59.93M
MIST:
-$63.04M
SPRY:
-$194.60M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MIST vs. SPRY — Risk / Return Rank
MIST
SPRY
MIST vs. SPRY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Milestone Pharmaceuticals Inc. (MIST) and Silverback Therapeutics Inc (SPRY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MIST | SPRY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.26 | ||
| Sortino ratioReturn per unit of downside risk | +0.69 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 0.94 | +0.08 |
| Calmar ratioReturn relative to maximum drawdown | -0.40 | -0.60 | +0.20 |
| Martin ratioReturn relative to average drawdown | -0.73 | -0.85 | +0.12 |
Loading charts...
Drawdowns
MIST vs. SPRY - Drawdown Comparison
The maximum MIST drawdown since its inception was -97.60%, roughly equal to the maximum SPRY drawdown of -95.20%. Use the drawdown chart below to compare losses from any high point for MIST and SPRY.
Loading charts...
Drawdown Indicators
| MIST | SPRY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.60% | -95.20% | -2.40% |
Max Drawdown (1Y)Largest decline over 1 year | -65.76% | -63.32% | -2.44% |
Max Drawdown (3Y)Largest decline over 3 years | -82.31% | -63.32% | -18.99% |
Max Drawdown (5Y)Largest decline over 5 years | -93.13% | -91.77% | -1.36% |
Current DrawdownCurrent decline from peak | -95.21% | -82.98% | -12.23% |
Average DrawdownAverage peak-to-trough decline | -78.35% | -78.26% | -0.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.81% | 44.52% | -8.71% |
Volatility
MIST vs. SPRY - Volatility Comparison
The current volatility for Milestone Pharmaceuticals Inc. (MIST) is 12.60%, while Silverback Therapeutics Inc (SPRY) has a volatility of 18.34%. This indicates that MIST experiences smaller price fluctuations and is considered to be less risky than SPRY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MIST | SPRY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.60% | 18.34% | -5.74% |
Volatility (6M)Calculated over the trailing 6-month period | 54.37% | 45.49% | +8.88% |
Volatility (1Y)Calculated over the trailing 1-year period | 83.25% | 66.37% | +16.88% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 77.72% | 80.08% | -2.36% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 104.98% | 80.79% | +24.19% |
Dividends
MIST vs. SPRY - Dividend Comparison
Neither MIST nor SPRY has paid dividends to shareholders.
Financials
MIST vs. SPRY - Financials Comparison
This section allows you to compare key financial metrics between Milestone Pharmaceuticals Inc. and Silverback Therapeutics Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MIST and SPRY have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SPRY has higher volatility (18.34%) compared to MIST (12.60%). In terms of maximum drawdown, MIST dropped -97.60% vs SPRY's -95.20%.
MIST currently has the higher Sharpe Ratio (-0.32 vs -0.58), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MIST and SPRY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer